ADMA Biologics ADMA and Takeda TAK are leading players in the plasma derived immunoglobulin sector. ADMA markets ...

The U.S. Intravenous Immunoglobulin Market plays a crucial role in treating immunodeficiency diseases and various autoimmune disorders, reflecting a steady evolution influenced by advanced therapies ...

The EC has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat CIDP.

A patient with severe postural orthostatic tachycardia syndrome (POTS) and mast cell activation syndrome (MCAS) received immunotherapy with low-dose naltrexone (LDN) and intravenous immunoglobulin ...

At Marshfield Children’s Hospital, Dr. Dolly Paw-ton, the facility dog, is helping make them happen. One Wausau family sees ...

The US Food and Drug Administration (FDA) has approved GSK's 200 mg/ml autoinjector of Benlysta for individuals aged five ...

Sanofi's riliprubart gets FDA orphan drug status for organ transplant rejection, unlocking key development perks.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Duchenne muscular dystrophy families are sharing stories about Elevidys complications on social media. But they aren’t ...

A panelist discusses recent advancements in bispecific antibody therapies for relapsed/refractory multiple myeloma, ...

The European Commission (EC) has approved argenx’s Vyvgart (efgartigimod alfa) subcutaneous (SC) injection to treat chronic ...